{"schema_version":"secwatch.filing_event.v1","accession":"0000721371-24-000036","form_type":"8-K","ticker":"CAH","cik":"0000721371","company_name":"CARDINAL HEALTH INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.777143+00:00","generated_at":"2026-06-03T01:08:21.667182+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cardinal Health Q3 non-GAAP EPS $2.08 (+20% YoY); raises FY24 EPS guidance to $7.30-$7.40","bullets":["Revenue $54.9B (+9% YoY); GAAP diluted EPS $1.05; non-GAAP diluted EPS $2.08 (+20%).","Pharma & Specialty Solutions segment profit $580M (+4%); Global Medical Products segment profit $20M vs -$46M a year ago.","FY2024 non-GAAP EPS guidance raised to $7.30-$7.40 (from $7.20-$7.35); non-GAAP effective tax rate guidance lowered to 22%-23%.","Preliminary FY2025 non-GAAP EPS guidance at least $7.50; Pharma segment profit growth at least 1%; GMPD segment profit ~$175M."],"urls":{"canonical":"https://secwatch.observer/filing/0000721371-24-000036","json":"https://secwatch.observer/filing/0000721371-24-000036.json","markdown":"https://secwatch.observer/filing/0000721371-24-000036.md","text":"https://secwatch.observer/filing/0000721371-24-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000036/0000721371-24-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000036/cah-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T01:08:21.667182+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f415d178f128e72baf0d133896ff84367d760565","claim":"CARDINAL HEALTH INC reported third quarter fiscal year 2024 results: revenue $54.9 billion, net income $258 million, EPS $1.05. Guidance raised.","evidence_excerpt":"Cardinal Health Reports Third Quarter Fiscal Year 2024 Results and Raises Fiscal Year 2024 Non-GAAP EPS Guidance • Revenue increased 9% to $54.9 billion • GAAP 1 operating earnings were $367 million; GAAP diluted EPS was $1.05 • Non-GAAP operating earnings increased 10% to $666 million; non-GAAP diluted EPS increased 20% to $2.08 • Fiscal year 2024 non-GAAP EPS guidance 2 raised and narrowed to $7.30 to $7.40, from $7.20 to $7.35 • Company provides preliminary fiscal year 2025 non-GAAP EPS guidance of at least $7.50","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/721371/000072137124000036/0000721371-24-000036-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter fiscal year 2024"},{"label":"Revenue","value":"$54.9 billion"},{"label":"Net income","value":"$258 million"},{"label":"EPS","value":"$1.05"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}